{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:08:17Z","timestamp":1794564497646,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13227-5","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T13:59:10Z","timestamp":1754315950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors associated with unfavourable treatment outcomes among patients with Multidrug-resistant Tuberculosis receiving outpatients care"],"prefix":"10.1038","volume":"15","author":[{"given":"Maria Jose","family":"Vadakunnel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi Jawaharlal","family":"Nehru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usharani","family":"Brammacharry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswari","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganthi","family":"Palavesam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anbazhagi","family":"Muthukumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasundaram Revathi","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavathy","family":"Pradhabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Sriramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanagavel","family":"Venkatchalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthuraj","family":"Muthaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"13227_CR1","unstructured":"Global & World Health Organization. Geneva: ; 2023 (2023). https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023"},{"key":"13227_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/ijmy.ijmy_244_21","volume":"11","author":"JM Johnson","year":"2022","unstructured":"Johnson, J. M., Mohapatra, A. K., Velladath, S. U. & Shettigar, K. S. Predictors of treatment outcomes in drug resistant tuberculosis observational retrospective study. Int. J. Mycobacteriol. 11, 38\u201346 (2022).","journal-title":"Int. J. Mycobacteriol"},{"key":"13227_CR3","doi-asserted-by":"publisher","first-page":"e0001020","DOI":"10.1371\/journal.pgph.0001020","volume":"3","author":"JR Bayowa","year":"2023","unstructured":"Bayowa, J. R. et al. Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis\/hiv at Mulago National referral hospital, uganda, a retrospective cohort study. PLOS Glob Public. Health. 3, e0001020 (2023).","journal-title":"PLOS Glob Public. Health"},{"key":"13227_CR4","doi-asserted-by":"publisher","first-page":"e0286194","DOI":"10.1371\/journal.pone.0286194","volume":"18","author":"A Alemu","year":"2023","unstructured":"Alemu, A. et al. Poor treatment outcome and associated risk factors among patients with Isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE. 18, e0286194 (2023).","journal-title":"PLoS ONE"},{"key":"13227_CR5","doi-asserted-by":"publisher","first-page":"e84815","DOI":"10.7554\/eLife.84815","volume":"12","author":"Y Chen","year":"2023","unstructured":"Chen, Y., Jiang, Q., Peierdun, M., Takiff, H. E. & Gao, Q. The mutational signatures of poor treatment outcomes on the drug-susceptible Mycobacterium tuberculosis genome. Elife 12, e84815 (2023).","journal-title":"Elife"},{"key":"13227_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12879-025-10655-6","volume":"25","author":"M Jose Vadakunnel","year":"2025","unstructured":"Jose Vadakunnel, M. et al. Impact of RpoB gene mutations and Rifampicin-resistance levels on treatment outcomes in Rifampicin-resistant tuberculosis. BMC Infect. Dis. 25, 284 (2025).","journal-title":"BMC Infect. Dis."},{"key":"13227_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.5588\/ijtld.23.0107","volume":"27","author":"DR Silva","year":"2023","unstructured":"Silva, D. R. et al. Isoniazid-resistant TB: treatment outcomes and impact of regimens with fluoroquinolones. Int. J. Tuberc Lung Dis. 27, 638\u2013640 (2023).","journal-title":"Int. J. Tuberc Lung Dis."},{"key":"13227_CR8","doi-asserted-by":"publisher","first-page":"e1003023","DOI":"10.1371\/journal.pmed.1003023","volume":"17","author":"G Sulis","year":"2023","unstructured":"Sulis, G. & Pai, M. Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med. 17, e1003023 (2023).","journal-title":"PLoS Med."},{"key":"13227_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.21037\/jtd.2019.01.58","volume":"11","author":"JY Kang","year":"2019","unstructured":"Kang, J. Y. et al. Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic L\u00f6wenstein-Jensen method for Isoniazid or rifampicin drug susceptibility tests in tuberculosis patients. J. Thorac. Dis. 11, 400\u2013409 (2019).","journal-title":"J. Thorac. Dis."},{"key":"13227_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3389\/fmicb.2018.02265","volume":"9","author":"H Javed","year":"2018","unstructured":"Javed, H. et al. Evaluation of genotype MTBDRplus and MTBDRsl assays for rapid detection of drug resistance in extensively drug-Resistant Mycobacterium tuberculosis isolates in Pakistan. Front. Microbiol. 9, 2265 (2018).","journal-title":"Front. Microbiol."},{"key":"13227_CR11","doi-asserted-by":"crossref","unstructured":"Bokop, C., Faye, L. M. & Apalata, T. Analysis of discordance between genotypic and phenotypic assays for rifampicin-resistant mycobacterium tuberculosis Isolated from healthcare facilities in Mthatha. Pathogens.12, 909 (2023).","DOI":"10.3390\/pathogens12070909"},{"key":"13227_CR12","doi-asserted-by":"publisher","first-page":"17552","DOI":"10.1038\/s41598-020-74432-y","volume":"10","author":"SS Smita","year":"2020","unstructured":"Smita, S. S. et al. Prevalence and factors associated with multidrug-resistant tuberculosis in South India. Sci. Rep. 10, 17552 (2020).","journal-title":"Sci. Rep."},{"key":"13227_CR13","unstructured":"India 2021,National TB Elimination Programme, Guidelines for Programmatic Management of Drug-resistant TB in, Central, T. B. & Division Ministry of Health and Family Welfare, Government of India, New Delhi, India."},{"key":"13227_CR14","doi-asserted-by":"publisher","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","volume":"58","author":"NN Linh","year":"2021","unstructured":"Linh, N. N. et al. World health organization treatment outcome definitions for tuberculosis: 2021 update. Eur. Respir J. 58, 2100804 (2021).","journal-title":"Eur. Respir J."},{"key":"13227_CR15","unstructured":"MedCalc: MedCalc\u2019s Relative risk calculator. MedCalc Software Ltd. (2024)."},{"key":"13227_CR16","doi-asserted-by":"crossref","unstructured":"Fekete, J. T. & Gyorffy, B. MetaAnalysisOnline.com: an online tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res, PMID, 39928123 (2025).","DOI":"10.2196\/64016"},{"key":"13227_CR17","unstructured":"Tuberculosis Multidrug-resistant (MDR-TB) or rifampicin-resistant TB (RR-TB), Global Tuberculosis Programme, World Health Organiztion, 20 May 2024)."},{"key":"13227_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4103\/ijmr.IJMR_1048_18","volume":"151","author":"A Sharma., Khanna","year":"2020","unstructured":"Sharma., Khanna, A. et al. Treatment outcomes of multidrug-resistant tuberculosis in delhi, India (2009\u20132014): A retrospective record-based study. Indian J. Med. Res. 151, 598\u2013603 (2020).","journal-title":"Indian J. Med. Res."},{"key":"13227_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jsps.2022.01.015","volume":"30","author":"A Muhammad","year":"2022","unstructured":"Muhammad, A. et al. Drug resistance patterns, treatment outcomes and factors affecting unfavourable treatment outcomes among extensively drug resistant tuberculosis patients in pakistan; a multicentre record review. Saudi Pharm. J. 30, 462\u2013469 (2022).","journal-title":"Saudi Pharm. J."},{"key":"13227_CR20","doi-asserted-by":"publisher","first-page":"e062857","DOI":"10.1136\/bmjopen-2022-062857","volume":"12","author":"V Panford","year":"2022","unstructured":"Panford, V. et al. Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti region,ghana: a retrospective, cross-sectional study. BMJ Open. 12, e062857 (2022).","journal-title":"BMJ Open."},{"key":"13227_CR21","doi-asserted-by":"publisher","first-page":"e0262318","DOI":"10.1371\/journal.pone.0262318","volume":"17","author":"MK Wakjira","year":"2022","unstructured":"Wakjira, M. K., Sandy, P. T. & Mavhandu-Mudzusi, A. H. Treatment outcomes of patients with MDR-TB and its determinants at referral hospitals in Ethiopia. PLoS ONE. 17, e0262318 (2022).","journal-title":"PLoS ONE"},{"key":"13227_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/tropicalmed7090244","volume":"7","author":"VP Giri","year":"2022","unstructured":"Giri, V. P. et al. The characteristics and patterns of Drug-Resistant pulmonary tuberculosis in Eastern India. Trop. Med. Infect. Dis. 7, 244 (2022).","journal-title":"Trop. Med. Infect. Dis."},{"key":"13227_CR23","doi-asserted-by":"crossref","unstructured":"Nair, D. et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. PHA. 7, 32\u201338 (2017).","DOI":"10.5588\/pha.16.0055"},{"key":"13227_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-018-3129-8","volume":"11","author":"A Melese","year":"2018","unstructured":"Melese, A. & Zeleke, B. Factors associated with poor treatment outcome of tuberculosis in Debre tabor, Northwest Ethiopia. BMC Res. Notes. 11, 1\u20136 (2018).","journal-title":"BMC Res. Notes"},{"key":"13227_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/jdmimsu.jdmimsu_50_23","volume":"18","author":"S Khan","year":"2018","unstructured":"Khan, S., Choudhary, S., Aurangabadkar, G. & Bankar, N. Sputum culture conversion among patients with drugresistant tuberculosis: A study of various predictors. J. Datta Meghe Inst. Med. Sci. Univ. 18, 255\u2013262 (2018).","journal-title":"J. Datta Meghe Inst. Med. Sci. Univ."},{"key":"13227_CR26","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.12669\/pjms.38.4.5058","volume":"38","author":"Z Iqbal","year":"2022","unstructured":"Iqbal, Z., Khan, M. A., Aziz, A. & Nasir, S. M. Time for culture conversion and its associated factors in multidrugresistant tuberculosis patients at a tertiary level hospital in peshawar, Pakistan. Pak J. Med. Sci. 38, 1009\u20131015 (2022).","journal-title":"Pak J. Med. Sci."},{"issue":"1","key":"13227_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/lungindia.lungindia_182_22","volume":"40","author":"KV Utpat","year":"2023","unstructured":"Utpat, K. V., Rajpurohit, R. & Desai, U. Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre bedaquiline (BDQ) era. Lung India. 40 (1), 19\u201323 (2023).","journal-title":"Lung India"},{"key":"13227_CR28","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/lungindia.lungindia_337_23","volume":"40","author":"NO Nwachukwu","year":"2023","unstructured":"Nwachukwu, N. O., Ulasi, A. E., Okoronkwo, C. U. & Unegbu, V. N. Pre\u2013extensively drug\u2013resistant tuberculosis among pulmonary multidrug\u2013resistant tuberculosis patients in Eastern Nigeria. Lung India. 40, 492\u2013495 (2023).","journal-title":"Lung India"},{"key":"13227_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jgar.2025.02.014","volume":"42","author":"G Diriba","year":"2025","unstructured":"Diriba, G. et al. Second-line drug resistance among multidrug-resistant tuberculosis patients in ethiopia: A laboratory-based surveillance. J. Glob Antimicrob. Resist. 42, 167\u2013174 (2025).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"13227_CR30","doi-asserted-by":"publisher","first-page":"e2019014","DOI":"10.4178\/epih.e2019014","volume":"41","author":"AH lduma","year":"2019","unstructured":"lduma, A. H. et al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in sudan: a case-control study. Epidemiol. Health. 41, e2019014 (2019).","journal-title":"Epidemiol. Health"},{"key":"13227_CR31","doi-asserted-by":"publisher","first-page":"e20180386","DOI":"10.36416\/1806-3756\/e20180386","volume":"46","author":"VM Soares","year":"2020","unstructured":"Soares, V. M. et al. Factors associated with tuberculosis and multidrug-resistant tuberculosis in patients treated at a tertiary referral hospital in the state of Minas gerais, Brazil. J. Bras. Pneumol. 46, e20180386 (2020).","journal-title":"J. Bras. Pneumol"},{"key":"13227_CR32","first-page":"103753","volume":"78","author":"VD Kajogoo","year":"2022","unstructured":"Kajogoo, V. D. et al. Treatment outcomes of multi-drug resistant tuberculosis patients with or without human immunodeficiency virus co-infection in Africa and asia: systematic review and meta-analysis. Ann. Med. Sur. 78, 103753 (2022).","journal-title":"Ann. Med. Sur"},{"key":"13227_CR33","doi-asserted-by":"crossref","unstructured":"Kumar, A., Harakuni, S., Paranjape, R., Korabu, A. S. & Prasad, J. B. Factors determining successful treatment outcome among notified tuberculosis patients in Belagavi district of North karnataka, India. CEGH 25,101505 (2024).","DOI":"10.1016\/j.cegh.2024.101505"},{"key":"13227_CR34","doi-asserted-by":"publisher","first-page":"e0263304","DOI":"10.1371\/journal.pone.0263304","volume":"17","author":"AY Soeroto","year":"2022","unstructured":"Soeroto, A. Y. et al. Factors associated with treatment outcome of MDR\/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia. PLoS ONE. 17, e0263304 (2022).","journal-title":"PLoS ONE"},{"key":"13227_CR35","doi-asserted-by":"publisher","first-page":"e059149","DOI":"10.1136\/bmjopen-2021-059149","volume":"12","author":"W Song","year":"2022","unstructured":"Song, W. et al. Impact of alcohol drinking and tobacco smoking on the drug-resistance of newly diagnosed tuberculosis: a retrospective cohort study in shandong, china, during 2004\u20132020. BMJ Open. 12, e059149 (2022).","journal-title":"BMJ Open."},{"key":"13227_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5588\/ijtld.19.0080","volume":"24","author":"EJ Ragan","year":"2020","unstructured":"Ragan, E. J. et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int. J. Tuberc Lung Dis. 24, 73\u201382 (2020).","journal-title":"Int. J. Tuberc Lung Dis."},{"key":"13227_CR37","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1513\/AnnalsATS.201312-447OC","volume":"11","author":"D Karthickeyan","year":"2014","unstructured":"Karthickeyan, D. et al. Does alcohol consumption during Multidrug-resistant tuberculosis treatment affect outcome?? A Population-based study in kerala, India. Annals ATS. 11, 712\u2013718 (2014).","journal-title":"Annals ATS"},{"key":"13227_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/ijmr.ijmr_607_22","volume":"157","author":"P Desikan","year":"2023","unstructured":"Desikan, P. et al. Heteroresistance to rifampicin & Isoniazid in clinical samples of patients with presumptive drug-resistant tuberculosis in central India. Indian J. Med. Res. 157, 174\u2013182 (2023).","journal-title":"Indian J. Med. Res."},{"key":"13227_CR39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5588\/ijtldopen.24.0343","volume":"1","author":"R Crowder","year":"2024","unstructured":"Crowder, R. et al. Impact of heteroresistance on treatment outcomes of people with drug-resistant TB. IJTLD Open. 1, 466\u2013472 (2024).","journal-title":"IJTLD Open."},{"key":"13227_CR40","first-page":"1974","volume":"218","author":"SS Shin","year":"2018","unstructured":"Shin, S. S. et al. Mixed Mycobacterium tuberculosis-Strain infections are associated with poor treatment outcomes among patients with newly diagnosed tuberculosis, independent of pretreatment heteroresistance. J. Infect. Dis. 218, 1974\u20131982 (2018).","journal-title":"J. Infect. Dis."},{"key":"13227_CR41","doi-asserted-by":"crossref","unstructured":"Munir, M. K., Saeed, M. S., Haider, S. Z. & Shamim, S. Comparison of short term and long term multidrug resistant tuberculosis treatment outcomes in tertiary care settings. J King Saud Univ. Sci 36,103133 (2024).","DOI":"10.1016\/j.jksus.2024.103133"},{"key":"13227_CR42","doi-asserted-by":"publisher","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","volume":"55","author":"S Abidi","year":"2020","unstructured":"Abidi, S. et al. Standardised shorter regimens versus individualised longer regimens for Rifampin or multidrug-resistant tuberculosis. Eur. Respir J. 55, 1901467 (2020).","journal-title":"Eur. Respir J."},{"key":"13227_CR43","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/tmi.13867","volume":"28","author":"L Mleoh","year":"2023","unstructured":"Mleoh, L. et al. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort. Trop. Med. Int. Health. 28, 357\u2013366 (2023).","journal-title":"Trop. Med. Int. Health"},{"key":"13227_CR44","doi-asserted-by":"publisher","first-page":"962809","DOI":"10.3389\/fpubh.2022.962809","volume":"3","author":"D Weiangkham","year":"2022","unstructured":"Weiangkham, D., Umnuaypornlert, A., Saokaew, S., Prommongkol, S. & Ponmark, J. Effect of alcohol consumption on relapse outcomes among tuberculosis patients: A systematic review and meta-analysis. Front. Public. Health. 3, 10, 962809 (2022).","journal-title":"Front. Public. Health"},{"key":"13227_CR45","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.jctube.2023.100398","volume":"33","author":"GK Getahun","year":"2023","unstructured":"Getahun, G. K. et al. Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in addis ababa, ethiopia: A retrospective follow-up study. J. Clin. Tuberc Other Mycobact. Dis. 33, 100398 (2023).","journal-title":"J. Clin. Tuberc Other Mycobact. Dis."},{"key":"13227_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.25259\/IJMS_45_2024","volume":"76","author":"RS Vaman","year":"2024","unstructured":"Vaman, R. S., Kalyanasundaram, M., Amina, T. P. & Murhekar, M. V. Epidemiology and outcomes of drug-resistant tuberculosis cases notified in a low-resource district in kerala, India 2017\u20132021 \u2013 A 5-year retrospective analysis. Indian J. Med. Sci. 76, 110\u2013116 (2024).","journal-title":"Indian J. Med. Sci."},{"key":"13227_CR47","doi-asserted-by":"publisher","first-page":"1136094","DOI":"10.3389\/fmed.2023.1136094","volume":"10","author":"Y Jiang","year":"2023","unstructured":"Jiang, Y. et al. Factors associated with loss to follow-up before and after treatment initiation among patients with tuberculosis: A 5-year observation in China. Front. Med. (Lausanne). 10, 1136094 (2023).","journal-title":"Front. Med. (Lausanne)"},{"key":"13227_CR48","doi-asserted-by":"crossref","unstructured":"Lecai, J. et al. Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in shenzhen, china: a retrospective cohort study. Front Public. Health 11,1134938 (2023).","DOI":"10.3389\/fpubh.2023.1134938"},{"key":"13227_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0041-1728971","volume":"57","author":"P Sandeep","year":"2021","unstructured":"Sandeep, P., Vishal, K., Shahnawaz, K. & Amit, S. Loss to Follow-up: A deceptive enigma. Ann. Natl. Acad. Med. Sci. (India). 57, 120\u2013122 (2021).","journal-title":"Ann. Natl. Acad. Med. Sci. (India)"},{"key":"13227_CR50","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/jac\/dkv360","volume":"71","author":"L Rigouts","year":"2016","unstructured":"Rigouts, L. et al. Specific GyrA gene mutations predict poor treatment outcome in MDR-TB. J. Antimicrob Chemother. 71, 314\u2013323 (2016).","journal-title":"J. Antimicrob Chemother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13227-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13227-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:26:04Z","timestamp":1757337964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13227-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13227"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13227-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Before starting the study, we received ethical clearance from the General Hospital Institution Ethics Committee at the Indira Gandhi Government General Hospital and Postgraduate Institute (Ref. No\/GHIEC\/2020\/243; June 2020). Before collecting data, we informed the hospital director and laboratory personnel about the study objectives. Since we used secondary data, we did not need the patients\u2019 informed consent. We did not include personal identifiers on the data collection sheet to protect the confidentiality of the participant\u2019s records. Additionally, access to secured data from participant records was restricted to the investigators only.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"28335"}}